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ABSTRACT
Objective: To determine whether treatment with
clarithromycin for respiratory tract infections was
associated with an increased risk of cardiovascular
(CV) events, arrhythmias or all-cause mortality
compared with other antibiotics.
Design: Retrospective cohort design comparing
clarithromycin monotherapy for lower (LRTI) or upper
respiratory tract infection (URTI) with other antibiotic
monotherapies for the same indication.
Setting: Routine primary care data from the UK
Clinical Practice Research Datalink and inpatient
data from the Hospital Episode Statistics
(HES).
Participants: Patients aged ≥35 years prescribed
antibiotic monotherapy for LRTI or URTI 1998–2012
and eligible for data linkage to HES.
Main outcome measures: The main outcome
measures were: adjusted risk of first-ever CV event,
within 37 days of initiation, in commonly prescribed
antibiotics compared with clarithromycin. Secondarily,
adjusted 37-day risks of first-ever arrhythmia and all-
cause mortality.
Results: Of 700 689 treatments for LRTI and eligible
for the CV analysis, there were 2071 CV events
(unadjusted event rate: 29.6 per 10 000 treatments). Of
691 998 eligible treatments for URTI, there were 688
CV events (9.9 per 10 000 treatments). In LRTI and
URTI, there were no significant differences in CV risk
between clarithromycin and all other antibiotics
combined: OR=1.00 (95% CI 0.82 to 1.22) and 0.82
(0.54 to 1.25), respectively. Adjusted CV risk in LRTI
versus clarithromycin ranged from OR=1.42 (cefalexin;
95% CI 1.08 to 1.86) to 0.92 (doxycycline; 0.64 to
1.32); in URTI, from 1.17 (co-amoxiclav; 0.68 to 2.01)
to 0.67 (erythromycin; 0.40 to 1.11). Adjusted
mortality risk versus clarithromycin in LRTI ranged
from 0.42 to 1.32; in URTI, from 0.75 to 1.43. For
arrhythmia, adjusted risks in LRTI ranged from 0.68 to
1.05; in URTI, from 0.70 to 1.22.
Conclusions: CV events were more likely after LRTI
than after URTI. When analysed by specific indication,
CV risk associated with clarithromycin was no different
to other antibiotics.
INTRODUCTION
There is an association between the inﬂam-
matory response to acute infection and
Strengths and limitations of this study
▪ This study examined cardiovascular and other
serious outcomes following therapy with clari-
thromycin and, for the first time, all other anti-
biotics prescribed for the same indication.
▪ The study considered lower and upper respira-
tory tract indications separately, enabling out-
comes to be compared by the severity of
antibiotics’ indication.
▪ Our use of linked primary and secondary care
data from the Clinical Practice Research Datalink
(CPRD) provided a large and nationally represen-
tative sample spanning 14 years and capturing
data from more than 1.6 million prescriptions.
▪ Our analyses were based on issued prescrip-
tions; we were unable to determine from the data
whether these were dispensed, whether patients
were compliant, or whether patients had been
advised to delay starting the prescribed
antibiotic.
▪ Indications for prescriptions are not directly
recorded in CPRD and therefore had to be
deduced.
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cardiovascular (CV) event risk. Lower respiratory tract
infection (LRTI) appears to be a trigger of acute myo-
cardial infarction and stroke.1–3 It has been postulated
that some antibiotic drug classes—notably the macro-
lides—are associated with electrophysiological side
effects such as QT prolongation, and therefore poten-
tially increase the risk of CV events.4 The British
National Formulary advises that macrolides ‘should be
used with caution in patients with a predisposition to
QT interval prolongation’.5 However, macrolides are
often used to treat more severe infections which should
be taken into account when evaluating CV risk since
antibiotic prescribing for LRTIs is different from that for
other indications. Thus, illness severity and the indica-
tion for antibiotic treatment should be taken into
account when analysing and interpreting any potential
association between antibiotic exposure and outcome
events.
This study was motivated by a recent paper that
reported a signiﬁcantly increased risk of cardiac death
associated with clarithromycin versus penicillin-V
(adjusted rate ratio (ARR) 1.76; 95% CI 1.08 to 2.85)
but not with roxithromycin (ARR=1.04; 1.08 to 2.85),
another macrolide antibiotic.6 However, the study did
not account for indication.
In a recent study of antibiotic treatment failure, we
identiﬁed almost 11 million ﬁrst-line antibiotic mono-
therapies, of which 39% were for upper respiratory tract
infections (URTIs) and 29% for LRTIs.7 Here, we used
the same data set to characterise the risk of various
severe outcome events, including CV events and arrhyth-
mia, in people exposed to clarithromycin for respiratory
infections versus other antibiotics. For the ﬁrst time, the
site of the infection was accounted for while adjusting
for other risk factors.
METHODS
Data source
The data sources were primary care data from the
Clinical Practice Research Datalink (CPRD) (formerly
the General Practice Research Database) and linked sec-
ondary care data from the Hospital Episode Statistics
(HES) for England.8 Approval for this study was granted
by CPRD’s Independent Scientiﬁc Advisory Committee
(protocol 15_012).
CPRD contains clinically rich, pseudonymised, longitu-
dinal data relating to more than 14 million patients, col-
lected from 660 primary care practices throughout the
UK (to January 2013). A proportion of participating
practices based in England, representing about 50% of
all CPRD patients, also take part in a linkage scheme by
which the records of eligible patients are anonymously
linked to other independent data sets.9 These include,
from 1997 to 2012, the HES repository, which collates
data on all hospital admissions occurring within
National Health Service hospitals in England.10 Patients
in linked practices are representative of the CPRD
population as a whole, which is in turn broadly represen-
tative of the UK population.9 11
CPRD applies data quality markers at patient and
general practice (GP) levels. Patient records are consid-
ered to have an acceptable research quality if they are
internally consistent with regard to age, sex, registration
and event dates and if the patient has been permanently
registered with the practice. Contributing practices are
assigned an ‘up to standard’ date from which their data
are judged to be of an acceptable quality with regard to
completeness, plausibility and continuity.12
Data recorded in CPRD include demographics; symp-
toms and diagnoses; prescriptions; immunisations;
results of investigations; referrals to specialists and sec-
ondary care; feedback from other care settings; and life-
style information relating to health behaviour, such as
body mass index (BMI) and smoking status. Diagnoses
in CPRD are recorded using the Read code classiﬁcation
and have been validated in a number of studies, showing
a high positive predictive value.13 Prescriptions are well
documented in the database as they are generated
within and automatically recorded by the general practi-
tioner’s practice software. The HES data include
primary and contributory causes of hospital admission
coded using the International Classiﬁcation of Diseases
(ICD)-10 classiﬁcation.
Patient selection
To improve ascertainment of CV events, only those
research quality patients eligible to have their records
linked to the HES data set were selected, thereby provid-
ing details of diagnoses and procedures related to hos-
pital admissions.
Patients younger than 35 years of age at therapy initi-
ation were excluded from the analysis due to the rarity
of CV events in this age group, although antibiotics were
commonly prescribed to these patients. Patients were
required to have been registered at an up-to-standard
practice for at least 365 days at therapy initiation so that
their prior history could be reliably characterised. Those
with prior CV events at therapy initiation were excluded
because of the difﬁculty, otherwise, in distinguishing
between new events associated with antibiotic exposure
and the re-recording by the general practitioner of an
earlier event considered relevant to the patient’s care.
Patients with previous arrhythmia were excluded from
the arrhythmia analysis for the same reason.
Identification of antibiotic therapy
The antibiotic therapies comprising the study cohorts
were selected from a data set of ﬁrst-line antibiotic
monotherapies if they began between 1998 and 2012
and had a single associated diagnosis, by clinical code,
for LRTI (eg, pneumonia, bronchitis, whooping cough)
or URTI (eg, pharyngitis, laryngitis, tonsillitis, sinusitis).
Episodes of monotherapy were identiﬁed as one or
more consecutive prescriptions for a single antibiotic
separated by no more than 30 days and uninterrupted
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by prescriptions for other antibiotic drug substances;
98% of all antibiotic prescriptions were monotherapy.
Only ﬁrst-line therapies were selected, where these were
deﬁned as ﬁrst-line if there were no prescriptions for
other antibiotics in the preceding 30 days. To prevent
previous antibiotic exposure from impacting on out-
comes, a minimum of 90 days between therapies was
required. Therapies were further excluded if follow-up
from antibiotic initiation to the end of registration (for
reasons other than death) or to the end of the data
excerpt was <37 days, this period having been selected
based on a presumed treatment course of 7 days plus
30 days’ follow-up. More than 80% of the antibiotics in
our data set were prescribed on a regimen of 7 days or
fewer, and 7 days was also the antibiotic treatment dur-
ation examined in the Danish study.6
For each of the two indications, the seven antibiotic
agents most frequently prescribed were examined and
reported separately; antibiotics less frequently prescribed
for each indication were grouped as ‘other’. The index
date was deﬁned as the date of the ﬁrst prescription in
the therapy episode. More than one episode could be
identiﬁed for any individual patient.
Figure 1 illustrates the overall process of selecting the
study data.
Study end points
The primary end point was the occurrence of a ﬁrst-ever
CV event in the 37 days following antibiotic therapy initi-
ation; this was determined for therapies for LRTI, URTI
and overall, with the last of these enabling ﬁndings to be
compared with previous studies.6 Secondary end points
were 37-day all-cause mortality and 37-day ﬁrst-ever
arrhythmia. Each analysis compared clarithromycin with
other antibiotics (the seven most commonly prescribed
and the ‘other’ group) and with all antibiotics com-
bined, for LRTI and URTI separately and together. Post
hoc, following a recent publication comparing CV end
points in clarithromycin and amoxicillin in the ﬁrst
2 weeks of exposure for Helicobacter pylori eradication,14
we also analysed these end points in the 14 days follow-
ing antibiotic initiation.
A CV event was deﬁned as the ﬁrst occurrence of fatal
or non-fatal myocardial infarction, stroke, angina, or
transient ischaemic attack, recorded by a Read or
ICD-10 code in either the primary care or linked HES
components of CPRD. An arrhythmia event was deﬁned
as a patient’s ﬁrst arrhythmia event recorded by a Read
or ICD-10 code in these sources.
Statistical methods
The baseline characteristics of patients at antibiotic
therapy initiation were determined for the most com-
monly prescribed antibiotics plus the ‘other’ group for
each indication. Multivariable logistic regression was
used to determine the independent associations
between these antibiotics and 37-day CV events, 37-day
all-cause mortality and 37-day arrhythmia events for
LRTI and URTI.
LRTI and URTI indications were analysed separately,
calculating separate ORs in order to investigate whether
ﬁndings in previous studies might be due to differences
in antibiotic prescription patterns between indications
(LRTIs and URTIs were also analysed together).
Clarithromycin was used as the reference category for
the logistic regression. Candidate covariates were age,
gender, smoking status, ethnicity, BMI, systolic blood
pressure (SBP), total cholesterol (TC), diabetes, number
of GP contacts in the prior year, Charlson comorbidity
index, the number of antiplatelet, lipid-lowering and
antihypertensive prescriptions in the year prior to index,
year of antibiotic therapy initiation and the number of
antibiotic therapies prescribed in the year prior to
index.
Clarithromycin is an inhibitor of cytochrome CYP3A4
and so should not be combined with statins that are
extensively metabolised by that enzyme. Statins not
metabolised by CYP3A4 (rosuvastatin, pravastatin and
ﬂuvastatin) are therefore preferred for use in conjunc-
tion with clarithromycin. However, it has been reported
that there may be an increased CV risk associated with
these drug combinations.15 To test this hypothesis, a sen-
sitivity analysis was planned that would include only
those patients receiving statins not metabolised by
CYP3A4; however, owing to low numbers of events, the
analysis was not carried out. Concomitant statin use was
therefore included as a categorical covariate in the
model.
To allow for any potential non-linear effects of predic-
tors on the outcome, continuous variables were consid-
ered for modelling using restricted cubic spline
functions to allow for potential non-linear effects.
Multivariable logistic regression was used to determine
the independent effects of antibiotic therapies for each
of the two indications for outcomes in the 37 days and,
post hoc, 14 days from initiation. All candidate covariates
were included in the ﬁnal model with no variable selec-
tion performed because it has been shown that exclud-
ing statistically insigniﬁcant variables does not improve
predictive accuracy and makes accurate CIs hard to
obtain. All statistical analyses were performed using R
software (R Core Team. R: A Language and
Environment for Statistical Computing. R Foundation
for Statistical Computing, Vienna, Austria. 2013. http://
www.r-project.org).
There were varying amounts of missing data for covari-
ates such as BMI (66% missing), SBP (37%) and TC
(69%; tables 1 and 2). The amount of missingness for
certain covariates precluded the use of imputation tech-
niques or the analysis of complete cases only. To address
this, continuous covariates with missing values were cate-
gorised with an additional ‘missing/not recorded’ cat-
egory. Similarly, categorical variables with missing values
were recoded with an additional ‘missing/not recorded’
category.
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Patient involvement
No patients were involved in the development of the
research question, in the design or conduct of this study,
or in the development of outcome measures. There are
no plans to disseminate the results of the research to
study participants or the relevant patient community.
RESULTS
Patients and cases
At the end of 2012, CPRD contained records of
58 450 685 antibiotic prescriptions issued to patients
with research quality records. From these, 1 604 056
ﬁrst-line monotherapy episodes were identiﬁed, 852 370
(53%) of which were associated with LRTI and 751 686
(47%) with URTI (47%; ﬁgure 1). All of these therapies
were eligible for inclusion in the all-cause mortality ana-
lysis. Selecting only those patients with no prior history
of a CV event at treatment initiation, there were
1 392 687 eligible cases: 700 689 (50%) for LRTI and
691 998 (50%) for URTI; these therapies were therefore
eligible for inclusion in the analysis of CV outcome.
Patients had no prior history of arrhythmia at the initi-
ation of 1 387 584 therapies, 720 642 (52%) for LRTI
and 666 942 (48%) for URTI, thus eligible for inclusion
in the analysis of arrhythmia.
Figure 1 Data flow diagram for
the selection of episodes of
first-line antibiotic monotherapy
reported in the CPRD. CPRD,
Clinical Practice Research
Datalink; CVD, cardiovascular
disease.
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Table 1 Baseline characteristics: first-line antibiotic monotherapies prescribed for LRTI
Clarithromycin Amoxicillin Cefalexin Co-amoxiclav Doxycycline Erythromycin Oxytetracycline Other*
Antibiotic monotherapies (all; mortality analysis), n 42 920 582 817 28 850 37 161 20 568 74 800 13 817 51 437
All patients, n 35 911 381 218 24 456 32 313 18 139 58 146 12 040 42 931
CVD-eligible therapies, n (%) 35 202 (82.0%) 482 054 (82.7%) 22 513 (78.0%) 29 444 (79.2%) 16 621 (80.8%) 63 391 (84.7%) 11 527 (83.4%) 39 937 (77.6%)
Arrhythmia-eligible therapies, n (%) 34 934 (81.4%) 496 126 (85.1%) 23 699 (82.1%) 30 741 (82.7%) 16 689 (81.1%) 64 373 (86.1%) 11 991 (86.8%) 42 089 (81.8%)
Women, n (%) 25 462 (59.3%) 320 708 (55.0%) 18 257 (63.2%) 19 106 (51.4%) 11 649 (56.6%) 45 912 (61.3%) 7369 (53.3%) 31 083 (60.4%)
Age at therapy initiation, years† 51/63/74 49/61/73 52/64/76 53/65/76 52/64/74 47/59/71 51/62/72 53/65/77
BMI, kg/m2, n (%):
Underweight 1010 (2.4%) 10 935 (1.8%) 638 (2.2%) 939 (2.6%) 555 (2.7%) 1357 (1.8%) 234 (1.7%) 1249 (2.4%)
Normal range 3974 (9.2%) 51 694 (8.9%) 2537 (8.8%) 3507 (9.4%) 2301 (11.2%) 6107 (8.2%) 1086 (7.9%) 4727 (9.2%)
Overweight/preobese 5412 (12.6%) 75 168 (12.9%) 3448 (11.9%) 4521 (12.2%) 3176 (15.4%) 8726 (11.7%) 1665 (12.1%) 5966 (11.6%)
Obese (class I–II) 4927 (11.5%) 63 985 (11.0%) 2987 (10.4%) 3692 (9.9%) 2822 (13.7%) 8119 (10.9%) 1318 (9.5%) 4776 (9.3%)
Obese (class III) 724 (1.7%) 9199 (1.6%) 468 (1.6%) 553 (1.5%) 423 (2.1%) 1429 (1.9%) 150 (1.1%) 753 (1.5%)
Missing/not recorded 26 873 (62.6%) 371 836 (63.8%) 18 772 (65.1%) 23 949 (64.4%) 11 291 (54.9%) 49 062 (65.6%) 9364 (67.7%) 33 966 (66.0%)
Smoking, n (%):
Never 19 513 (45.5%) 262 022 (45.0%) 12 929 (44.8%) 15 930 (42.9%) 8553 (41.6%) 34 309 (45.9%) 6277 (45.4%) 23 055 (44.8%)
Former 12 893 (30.0%) 162 763 (27.9%) 8094 (28.1%) 11 275 (30.3%) 6707 (32.6%) 19 630 (26.2%) 3633 (26.3%) 14 780 (28.7%)
Current 10 190 (23.7%) 152 764 (26.2%) 7354 (25.5%) 9544 (25.7%) 5239 (25.5%) 20 313 (27.2%) 3782 (27.4%) 12 741 (24.8%)
Missing/not recorded 324 (0.8%) 5268 (0.9%) 473 (1.6%) 412 (1.1%) 69 (0.3%) 548 (0.7%) 125 (0.9%) 861 (1.7%)
SBP, mm Hg, n (%):
Normal 4316 (10.1%) 54623 (9.4%) 2750 (9.5%) 3544 (12.3%) 2212 (10.8%) 7110 (9.5%) 937 (6.8%) 4667 (9.1%)
Normal high 12 177 (28.4%) 157 921 (27.1%) 7726 (26.8%) 9817 (34.0%) 6504 (31.6%) 19 519 (26.1%) 3204 (23.2%) 12 536 (24.4%)
Hypertension 12 471 (29.1%) 170 779 (29.3%) 8990 (31.2%) 11 125 (38.6%) 6010 (29.2%) 21 197 (28.3%) 4119 (29.8%) 16 056 (31.2%)
Missing/not recorded 13 956 (32.5%) 199 494 (34.2%) 9384 (32.5%) 12 675 (43.9%) 5842 (28.4%) 26 974 (36.1%) 5557 (40.2%) 18 178 (35.3%)
GP contacts (year prior)† 4/8/15 3/7/12 4/8/15 4/8/14 4/9/16 3/7/12 3/7/12 4/8/15
Ethnicity, n (%)
Non-white 1400 (3.3%) 19 092 (3.3%) 693 (2.4%) 1237 (3.3%) 463 (2.3%) 2344 (3.1%) 219 (1.6%) 1167 (2.3%)
Unknown 4035 (9.4%) 53 199 (9.1%) 2682 (9.3%) 3717 (10.0%) 1746 (8.4%) 7053 (9.4%) 1284 (9.3%) 5440 (10.6%)
White 33 584 (78.2%) 448 294 (76.9%) 23 070 (80.0%) 28 690 (77.2%) 16 463 (80.1%) 57 588 (77.0%) 10 894 (78.8%) 40 802 (79.3%)
Missing/not recorded 3901 (9.1%) 62 232 (10.7%) 2405 (8.3%) 3517 (9.5%) 1896 (9.2%) 7815 (10.5%) 1420 (10.3%) 4028 (7.8%)
Diabetes, n (%) 4759 (11.1%) 58 866 (10.1%) 3262 (11.3%) 4255 (11.4%) 2369 (11.5%) 6842 (9.1%) 1069 (7.7%) 5695 (11.1%)
TC, mmol/L, n (%)
Desirable 12 290 (28.6%) 160 601 (27.6%) 7725 (26.8%) 10 232 (27.5%) 7069 (34.4%) 17 961 (24.0%) 2881 (20.9%) 12 460 (24.2%)
Borderline high 2322 (5.4%) 28 102 (4.8%) 1419 (4.9%) 1684 (4.5%) 1108 (53.9%) 3671 (4.9%) 601 (4.3%) 2306 (45.0%)
High 908 (2.1%) 10 722 (1.8%) 533 (1.8%) 619 (1.7%) 408 (2.0%) 1438 (1.9%) 236 (1.7%) 943 (1.8%)
Missing/not recorded 27 400 (63.8%) 383 392 (65.8%) 19 173 (66.5%) 24 626 (66.3%) 11 983 (58.3%) 51 730 (69.2%) 10 099 (73.1%) 35 728 (69.5%)
Lipid-lowering prescriptions (count year prior)†‡ 0/0/0 0/0/0 0/0/0 0/0/0 0/0/4 0/0/0 0/0/0 0/0/0
Antihypertensive prescriptions (count year prior)†‡ 0/0/7 0/0/7 0/0/7 0/0/7 0/0/7 0/0/6 0/0/6 0/0/7
Antiplatelet prescriptions (count year prior)†‡ 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0
Antibiotic prescriptions (count year prior)†‡ 1/2/3 1/1/2 1/2/3 1/2/3 1/2/3 1/1/2 1/1/3 1/2/3
*Forty-six antibiotics (10 most frequently used : penicillin-V, flucloxacillin, cefradine, azithromycin, tetracycline, ampicillin, cefadroxil, ofloxacin, levofloxacin, nitrofurantoin).
†Lower quartile/median/upper quartile.
‡Inclusive of index date.
BMI: <20 kg/m2—underweight, 20–24 kg/m2—normal, 25–29 kg/m2—overweight/preobese, 30–39 kg/m2—obese (class I—II), >40 kg/m2—obese (class III).
SBP: <120 mm Hg—normal, 120–139 mm Hg—normal high, >140 kg/m2—hypertension.
TC: <5.2 mmol/L—desirable, 5.2–6.1 mmol/L—borderline high, >6.1 mmol/L—high.
BMI, body mass index; CVD, cardiovascular disease; GP, general practitioner; LRTI, lower respiratory tract infection; SBP, systolic blood pressure; TC, total cholesterol.
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Table 2 Baseline characteristics: first-line antibiotic monotherapies prescribed for URTI
Clarithromycin Amoxicillin Cefalexin Co-amoxiclav Doxycycline Erythromycin Penicillin-V Other*
Antibiotic monotherapies (all; mortality analysis), n 20 303 380 258 23 581 25 823 72 226 66 607 121 238 41 650
All patients, n 17 818 280 614 20 251 22 862 56 392 53 510 103 580 36 916
CVD-eligible therapies, n (%) 18 657 (91.9%) 345 636 (90.9%) 21 122 (89.6%) 23 874 (92.5%) 67 649 (93.7%) 61.854 (92.9%) 115 936 (95.6%) 37 270 (89.5%)
Arrhythmia-eligible therapies, n (%) 17 600 (86.7%) 335 160 (88.1%) 20 618 (87.4%) 22 852 (88.5%) 63 806 (88.3%) 59 401 (89.1%) 111 211 (91.7%) 36 294 (87.1%)
Women, n (%) 13 958 (68.7%) 244 927 (64.4%) 16 693 (70.8%) 16 379 (63.4%) 50 164 (69.5%) 46 352 (69.6%) 76 028 (62.7%) 28 531 (68.5%)
Age at therapy initiation, years† 43/53/64 43/53/65 43/54/65 43/52/62 43/52/61 41/50/61 38/43/54 44/55/66
BMI, kg/m2, n (%)
Underweight 293 (1.4%) 4846 (1.3%) 356 (1.5%) 268 (1.1%) 795 (1.2%) 774 (1.2%) 1028 (0.8%) 584 (1.4%)
Normal range 1851 (9.1%) 32 753 (8.6%) 2102 (8.9%) 2022 (7.8%) 6121 (7.8%) 5190 (7.8%) 8657 (7.1%) 3637 (9.7%)
Overweight/preobese 2448 (12.1%) 45 419 (11.9%) 2763 (11.7%) 2801 (10.8%) 7912 (10.7%) 71 386 (10.7%) 11 428 (9.4%) 4807 (11.5%)
Obese (class I–II) 2146 (10.6%) 36 993 (9.7%) 2163 (9.2%) 2302 (8.9%) 6342 (9.9%) 6612 (9.9%) 10 295 (8.5%) 3869 (9.3%)
Obese (class III) 349 (1.7%) 5388 (1.4%) 341 (1.4%) 328 (1.3%) 910 (1.7%) 1133 (1.7%) 1739 (1.4%) 546 (1.3%)
Missing/not recorded 13 216 (65.1%) 254 859 (67.1%) 15 856 (67.2%) 18 102 (70.1) 50 146 (68.7%) 45 762 (68.7%) 88 091 (72.7%) 28 207 (67.7%)
Smoking, n (%):
Never 11 500 (56.7%) 213 405 (56.1%) 13 350 (56.6%) 14 383 (55.7%) 41 466 (57.4%) 37 966 (57.0%) 70 185 (57.9%) 23 761 (57%)
Former 4838 (23.8%) 87 834 (23.1%) 5332 (22.6%) 5750 (22.3%) 16 129 (22.3%) 14 143 (21.2%) 24 383 (20.1%) 9230 (22.2%)
Current 3889 (19.2%) 77 209 (20.3%) 4783 (20.3%) 5548 (21.5%) 14 365 (19.9%) 14 209 (21.3%) 25 886 (21.4%) 8432 (20.2%)
Missing/not recorded 76 (0.3%) 1810 (0.5%) 116 (0.5%) 142 (0.5%) 266 (0.4%) 289 (0.4%) 784 (0.6%) 227 (0.5%)
SBP, mm Hg, n (%):
Normal 2400 (11.8%) 41 534 (10.9%) 2664 (11.3%) 2762 (10.7%) 7859 (10.9%) 7481 (11.2%) 14 592 (12.0%) 4414 (10.6%)
Normal high 5729 (28.2%) 100 788 (26.5%) 6198 (26.3%) 6730 (26.1%) 18 878 (26.1%) 17 124 (25.7%) 27 673 (22.8%) 10 388 (24.9%)
Hypertension 4418 (21.8%) 89 787 (23.6%) 5788 (24.5%) 5506 (21.3%) 15 461 (21.4%) 14 297 (21.5%) 18 593 (15.3%) 10 494 (25.2%)
Missing/not recorded 7756 (38.2%) 148 149 (39.0%) 8931 (37.9%) 10 825 (41.9%) 30 028 (41.6%) 27 705 (41.6%) 60 380 (49.8%) 16 354 (39.3%)
GP contacts (year prior)† 3/7/12 2/6/10 3/6/11 3/6/10 3/6/11 3/6/10 2/4/8 3/6/12
Ethnicity, n (%)
Non-white 864 (4.2%) 19 236 (5.1%) 903 (3.8%) 1083 (4.2%) 2012 (2.8%) 3262 (4.9%) 6607 (5.0%) 1499 (3.6%)
Unknown 1831 (1.0%) 33 981 (8.9%) 2066 (8.8%) 2435 (9.4%) 7165 (9.9%) 5967 (8.9%) 11 548 (9.9%) 3855 (9.3%)
White 15 058 (74.2%) 275 639 (72.5%) 17 664 (74.9%) 18 426 (71.4%) 52 231 (72.3%) 48 594 (73.0%) 82 936 (68.4%) 31 455 (75.5%)
Missing/not recorded 2550 (12.6%) 51 402 (13.5%) 2948 (12.5%) 3879 (15%) 10 818 (15%) 8784 (13.2%) 20 287 (16.7%) 4841 (11.6%)
Diabetes, n (%) 1520 (7.5%) 27 603 (7.3%) 1677 (7.1%) 1708 (6.6%) 3985 (5.5%) 4234 (6.4%) 5681 (4.7%) 3071 (7.4%)
TC, mmol/L, n (%):
Desirable 4669 (23.0%) 84 779 (22.3%) 5000 (21.2%) 5215 (20.2%) 13 842 (19.2%) 12 507 (18.8%) 17 136 (14.1%) 8060 (19.4%)
Borderline high 1069 (5.3%) 18 072 (4.8%) 1086 (4.6%) 1144 (4.4%) 3492 (4.8%) 3106 (4.7%) 3840 (3.2%) 1914 (4.6%)
High 451 (2.2%) 6805 (1.8%) 450 (1.9%) 415 (1.6%) 1355 (1.9%) 1172 (1.8%) 1459 (1.2%) 736 (1.8%)
Missing/not recorded 14 114 (69.5%) 270 602 (71.2%) 17 045 (72.3%) 19 049 (73.8%) 53 537 (74.1%) 49 822 (74.8%) 98 803 (81.5%) 30 940 (74.3%)
Lipid-lowering prescriptions (count year prior)†‡ 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0
Antihypertensive prescriptions (count year prior)†‡ 0/0/2 0/0/2 0/0/3 0/0/0 0/0/0 0/0/0 0/0/0 0/0/3
Antiplatelet prescriptions (count year prior)†‡ 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0
Antibiotic prescriptions (count year prior)†‡ 1/2/3 1/1/2 1/2/3 1/1/2 1/1/2 1/1/2 1/1/2 1/2/3
*Thirty-one antibiotics (10 most frequently used: ciprofloxacin, flucloxacillin, tetracycline, cefradine, cefadroxil, azithromycin, metronidazole, nitrofurantoin, ampicillin, co-fluampicil).
†Lower quartile/median/upper quartile.
‡Inclusive of index date.
BMI: <20 kg/m2—underweight, 20–24 kg/m2—normal, 25–29 kg/m2—overweight/preobese, 30–39 kg/m2—obese (class I–II), >40 kg/m2—obese (class III).
SBP: <120 mm Hg—normal, 120–139 mm Hg—normal high, >140 kg/m2—hypertension.
TC: <5.2 mmol/L—desirable, 5.2–6.1 mmol/L—borderline high, >6.1 mmol/L—high.
BMI, body mass index; CVD, cardiovascular disease; GP, general practitioner; URTI, upper respiratory tract infection; SBP, systolic blood pressure; TC, total cholesterol.
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Baseline characteristics
The overall demographics, biochemical test results, pat-
terns of baseline comorbidity and numbers of prior ther-
apies were generally similar between the antibiotics
prescribed for LRTI and URTI, as detailed in tables 1
and 2. There were more women with URTIs (65.6% vs
56.3%), while patients with LRTIs were older (61.8 vs
53.3 years).
Antibiotic treatment
Within the LRTI group, the most commonly prescribed
antibiotic was amoxicillin (68%), followed by erythro-
mycin (9%), clarithromycin (5%), co-amoxiclav (4%),
cefalexin (3%), doxycycline (2%) and oxytetracycline
(2%). The most frequently prescribed antibiotic in the
URTI group was amoxicillin (51%), followed by
penicillin-V (16%), doxycycline (10%), erythromycin
(9%), co-amoxiclav (3%), cefalexin (3%) and clarithro-
mycin (3%). Thus, the most commonly prescribed anti-
biotics were the same for both respiratory infection
categories, with the exception of oxytetracycline for
LRTI and penicillin-V for URTI (almost exclusively for
tonsillitis/pharyngitis). The eight most frequently pre-
scribed antibiotics overall include the most commonly
used antibiotics for both LRTIs and URTIs.
CV event risk
Within the LRTI group, the unadjusted ﬁrst-ever CV
event rates within 14 and 37 days of treatment initiation
were 15.7 and 29.6 per 10 000 therapies, respectively
(table 3). The adjusted 37-day risk of ﬁrst-ever CV events
was the same in clarithromycin therapies as in all other
antibiotics combined (OR=1.00; 95% CI 0.82 to 1.22).
When analysing each of the most frequently used anti-
biotics for LRTI separately versus clarithromycin, the
37-day adjusted risk of CV event was highest in cefalexin
therapies (1.42; 1.08 to 1.86) and lowest in doxycycline
therapies (0.92; 0.64 to 1.32; table 4; ﬁgure 2).
Within the URTI group, the unadjusted ﬁrst-ever CV
event rates within 14 and 37 days of antibiotic initiation
were 5.0 and 9.9 CV events per 10 000 therapies (table 3).
The adjusted 37-day risk of a CV event was lower in all
other antibiotics combined than in clarithromycin therap-
ies (0.82; 0.54 to 1.25). When analysing each of the most
frequently used antibiotics for URTI separately versus clari-
thromycin, the adjusted 37-day risk of a CV event was
highest in co-amoxiclav therapies (1.17; 0.68 to 2.01) and
lowest in erythromycin therapies (0.67; 0.40 to 1.11).
Within the LRTI and URTI combined group, the
adjusted rates were 10.4 and 19.8 CV events per 10 000
therapies in the 14 and 37 days following initiation,
respectively (table 3). The adjusted 37-day risk of a CV
event was lower in all other antibiotics combined than in
clarithromycin therapies (0.93; 0.78 to 1.11). When ana-
lysing each of the most frequently used antibiotics for
URTI separately versus clarithromycin, the 37-day risk of
CV risk was highest in cefalexin therapies (1.25; 0.98 to
1.59) and lowest in penicillin-V therapies (0.71; 0.53 to
0.95).
The 14-day risk of CV events in the LRTI group was
comparable between all other antibiotics combined and
clarithromycin (0.93; 0.71 to 1.21). In the URTI group,
there was no difference (0.99; 0.53 to 1.86; table 4).
All-cause mortality risk
Within the LRTI group, unadjusted all-cause mortality
rates of 43.2 and 86.8 deaths per 10 000 therapies were
found in the 14 and 37 days following initiation, respect-
ively (table 3). The adjusted 37-day risk of all-cause mor-
tality was lower in all antibiotics combined than in
clarithromycin therapies (0.85; 0.77 to 0.94). When ana-
lysing each of the most frequently used antibiotics for
LRTI separately versus clarithromycin, the adjusted
37-day all-cause mortality risk was highest in
co-amoxiclav therapies (1.32; 1.17 to 1.51) and lowest in
oxytetracycline therapies (0.42; 0.31 to 0.56; table 4;
ﬁgure 2).
In the URTI group, there were unadjusted rates of 2.7
and 7.9 deaths per 10 000 therapies, in the 14 and
37 days following initiation, respectively (table 3). The
adjusted 37-day risk of all-cause mortality was higher in
all other antibiotics combined than in clarithromycin
therapies (1.06; 0.65 to 1.74). When analysing each of
the most frequently used antibiotics for URTI separately
versus clarithromycin, the adjusted 37-day all-cause mor-
tality risk was highest in co-amoxiclav therapies (1.43;
0.76 to 2.67) and lowest in penicillin-V therapies (0.75;
0.41 to 1.34).
In the LRTI and URTI combined group, there were
corresponding unadjusted rates of 24.2 and 49.8 deaths
per 10 000 therapies, respectively. The adjusted 37-day
risk of all-cause mortality was higher in all other antibio-
tics combined than in clarithromycin therapies (0.80;
0.73 to 0.89). When analysing each of the most fre-
quently used antibiotics for LRTI and URTI combined
versus clarithromycin, the 37-day all-cause mortality risk
was highest in co-amoxiclav therapies (1.32; 1.16 to 1.49)
and lowest in penicillin-V therapies (0.29; 0.21 to 0.39).
The 14-day OR for all-cause mortality in the LRTI
group was similar to the 37-day result (0.83; 0.72 to 0.95,
table 4); however, in the URTI analysis, the 14-day OR
differed slightly from the 37-day result (1.21; 0.50 to
2.98). However, the CIs of the 14-day and 37-day ORs for
all-cause mortality spanned 1.
Arrhythmia event risk
Within the LRTI group, there were unadjusted rates of
19.3 and 49.3 arrhythmia events per 10 000 therapies
within 14 and 37 days of therapy initiation, respectively
(table 3). The adjusted 37-day risk of ﬁrst-ever arrhyth-
mia was lower in all other antibiotics combined than in
clarithromycin therapies (0.88; 0.76 to 1.01). When ana-
lysing each of the most frequently prescribed antibiotics
for LRTI separately, the adjusted 37-day risk of arrhyth-
mia was highest in co-amoxiclav therapies (1.05; 0.86 to
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Table 3 Crude event rates per 10 000 therapies for 14-day and 37-day all-cause mortality and CV and arrhythmia events, by first-line antibiotic monotherapy and by
indication
14-day analysis 37-day analysis
CV Death Arrhythmia CV Death Arrhythmia
Events Crude rate Events Crude rate Events Crude rate Events Crude rate Events Crude rate Events Crude rate
Lower respiratory tract infection
Overall 1102 15.7 3690 43.2 1393 19.3 2071 29.6 7401 86.8 3359 49.3
Amoxicillin 686 14.2 2177 37.3 948 19.1 1326 27.5 4315 74.0 2199 44.3
Erythromycin 92 14.5 251 33.5 97 15.0 163 25.7 469 62.7 245 38.1
Clarithromycin 58 16.4 225 52.2 75 21.1 103 29.3 449 104.6 197 55.5
Co-amoxiclav 67 22.7 302 81.1 65 21.1 118 40.1 614 165.2 188 61.2
Cefalexin 71 31.5 251 86.9 48 20.2 111 49.3 471 163.3 114 48.1
Doxycycline 25 15.0 47 22.7 37 22.1 43 25.9 122 59.3 90 53.9
Oxytetracycline 16 13.9 17 12.3 16 13.3 39 33.8 49 35.5 39 32.5
Other* 87 21.8 420 81.6 107 25.4 168 42.1 912 177.3 287 55.1
Upper respiratory tract infections
Overall 350 5.0 203 2.7 555 8.3 688 9.9 591 7.9 1422 21.3
Amoxicillin 187 5.4 122 3.2 316 9.4 368 10.6 359 9.4 773 23.1
Penicillin-V 40 10.7 15 1.2 45 4.0 68 5.9 32 2.6 138 12.4
Doxycycline 33 4.9 10 1.4 54 8.4 71 10.5 33 4.6 140 21.9
Erythromycin 25 4.0 15 2.2 51 8.6 46 7.4 39 5.9 137 23.1
Co-amoxiclav 14 5.9 6 2.3 23 10.0 32 13.4 25 9.7 62 27.1
Cefalexin 12 5.7 8 3.4 25 12.1 25 10.6 27 11.4 55 23.3
Clarithromycin 10 5.3 5 2.5 12 6.8 23 11.3 17 8.4 43 24.4
Other† 29 2.5 22 5.3 29 8.0 55 14.8 59 14.2 74 20.4
Upper and lower respiratory tract infections combined
Overall 1452 10.4 3893 24.2 1948 14.0 2759 19.8 7992 49.8 4781 34.4
Amoxicillin 873 10.5 2299 23.8 87 16.3 1694 20.5 4674 48.5 2972 35.8
Erythromycin 117 9.3 266 18.8 148 11.9 209 16.7 508 35.9 382 30.9
Penicillin-V 43 3.6 22 1.8 53 4.6 73 6.1 52 4.2 148 13.0
Doxycycline 58 6.9 57 6.1 91 11.3 114 13.5 155 16.7 230 28.6
Co-amoxiclav 81 15.2 308 48.8 81 15.2 150 28.1 639 101.5 250 46.6
Clarithromycin 68 12.6 230 36.2 68 12.6 126 23.4 466 73.7 240 45.2
Cefalexin 83 19.0 259 49.4 83 19.0 136 25.4 498 95.0 169 38.1
Oxytetracycline 25 11.4 18 7.1 25 11.4 53 24.2 53 21.0 55 24.8
Other‡ 104 16.2 434 55.3 104 16.2 204 31.9 947 120.7 335 51.3
*Forty-six antibiotics (10 most frequently used: penicillin-V, flucloxacillin, cefradine, azithromycin, tetracycline, ampicillin, cefadroxil, ofloxacin, levofloxacin, nitrofurantoin).
†Thirty-one antibiotics (10 most frequently used: ciprofloxacin, flucloxacillin, tetracycline, cefradine, cefadroxil, azithromycin, metronidazole, nitrofurantoin, ampicillin, co-fluampicil).
‡Forty-nine antibiotics (10 most frequently used: trimethroprim, cefaclor, ciprofloxacin, flucloxacillin, cefradine, tetracycline, azithromycin, ampicillin, cefadroxil, nitrofurantoin, metronidazole).
CV, cardiovascular.
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Table 4 Adjusted ORs versus clarithromycin for 14-day and 37-day all-cause mortality and CV and arrhythmia events, by first-line antibiotic monotherapy and by
indication
14-day OR (95% CI) 37-day OR (95% CI)
CV events All-cause mortality Arrhythmia events CV events All-cause mortality Arrhythmia events
Lower respiratory tract infection
All antibiotics combined 0.93 (0.71 to 1.21) 0.83 (0.72 to 0.95) 1.01 (0.80 to 1.27) 1.00 (0.82 to 1.22) 0.85 (0.77 to 0.94) 0.88 (0.76 to 1.01)
Amoxicillin 0.86 (0.66 to 1.13) 0.75 (0.65 to 0.86) 1.01 (0.80 to 1.28) 0.95 (0.78 to 1.16) 0.76 (0.69 to 0.84) 0.85 (0.73 to 0.98)
Erythromycin 0.98 (0.71 to 1.37) 0.82 (0.69 to 0.99) 0.87 (0.64 to 1.18) 0.98 (0.76 to 1.26) 0.77 (0.68 to 0.89) 0.81 (0.67 to 0.97)
Co-amoxiclav 1.17 (0.80 to 1.62) 1.28 (1.07 to 1.53) 0.98 (0.70 to 1.36) 1.13 (0.87 to 1.48) 1.32 (1.17 to 1.51) 1.05 (0.86 to 1.29)
Cefalexin 1.60 (1.26 to 2.27) 1.28 (1.06 to 1.55) 0.96 (0.66 to 1.38) 1.42 (1.08 to 1.86) 1.26 (1.10 to 1.45) 0.84 (0.66 to 1.06)
Doxycycline 0.96 (0.60 to 1.54) 0.46 (0.33 to 0.64) 0.99 (0.67 to 1.47) 0.92 (0.64 to 1.32) 0.58 (0.47 to 0.72) 0.95 (0.74 to 1.22)
Oxytetracycline 0.80 (0.46 to 1.39) 0.29 (0.17 to 0.47) 0.76 (0.44 to 1.31) 1.09 (0.75 to 1.59) 0.42 (0.31 to 0.56) 0.68 (0.48 to 0.95)
Other* 1.00 (0.71 to 1.39) 1.16 (0.98 to 1.37) 1.15 (0.85 to 1.55) 1.09 (0.85 to 1.40) 1.32 (1.17 to 1.48) 1.15 (0.96 to 1.38)
Upper respiratory tract infection
All antibiotics combined 0.99 (0.53 to 1.86) 1.21 (0.50 to 2.98) 1.39 (0.80 to 2.41) 0.82 (0.54 to 1.25) 1.06 (0.65 to 1.74) 0.94 (0.69 to 1.27)
Amoxicillin 0.94 (0.50 to 1.80) 0.95 (0.35 to 2.63) 1.44 (0.81 to 2.57) 0.79 (0.51 to 1.20) 1.09 (0.67 to 1.80) 0.95 (0.69 to 1.29)
Penicillin-V 1.03 (0.51 to 2.08) 1.19 (0.38 to 3.71) 0.85 (0.45 to 1.61) 0.76 (0.47 to 1.23) 0.75 (0.41 to 1.34) 0.70 (0.50 to 0.99)
Doxycycline 1.07 (0.53 to 2.18) 0.67 (0.20 to 2.33) 1.43 (0.76 to 2.67) 1.00 (0.62 to 1.60) 0.84 (0.46 to 1.52) 1.01 (0.72 to 1.42)
Erythromycin 0.85 (0.41 to 1.79) 1.16 (0.37 to 3.65) 1.42 (0.76 to 2.68) 0.67 (0.40 to 1.11) 0.98 (0.55 to 1.76) 1.04 (0.74 to 1.47)
Co-amoxiclav 1.19 (0.53 to 2.18) 0.88 (0.22 to 3.57) 1.68 (0.83 to 3.38) 1.17 (0.68 to 2.01) 1. 43 (0.76 to 2.67) 1.22 (0.83 to 1.81)
Cefalexin 0.96 (0.41 to 2.24) 0.57 (0.27 to 2.57) 1.73 (0.86 to 3.45) 0.84 (0.48 to 1.50) 1.10 (0.59 to 2.05) 1.05 (0.70 to 1.57)
Other† 1.21 (0.58 to 2.49) 1.17 (0.37 to 3.70) 1.13 (0.57 to 2.22) 0.95 (0.58 to 1.56) 1.35 (0.78 to 2.35) 0.79 (0.54 to 1.15)
Lower and upper respiratory tract infections combined
All antibiotics combined 0.90 (0.71 to 1.15) 0.78 (0.68 to 0.89) 1.01 (0.82 to 1.3) 0.93 (0.78 to 1.11) 0.80 (0.73 to 0.89) 0.86 (0.76 to 0.98)
Amoxicillin 0.86 (0.67 to 1.10) 0.72 (0.63 to 0.83) 1.05 (0.84 to 1.30) 0.90 (0.75 to 1.08) 0.74 (0.67 to 0.82) 0.85 (0.75 to 0.98)
Erythromycin 0.92 (0.68 to 1.24) 0.78 (0.65 to 0.96) 0.93 (0.72 to 1.22) 0.88 (0.71 to 1.01) 0.73 (0.65 to 0.84) 0.84 (0.72 to 0.99)
Penicillin-V 0.79 (0.53 to 1.16) 0.25 (0.16 to 0.40) 0.60 (0.42 to 0.75) 0.71 (0.53 to 0.95) 0.29 (0.21 to 0.39) 0.57 (0.47 to 0.71)
Doxycycline 0.86 (0.61 to 1.23) 0.34 (0.26 to 0.46) 0.95 (0.70 to 1.27) 0.90 (0.70 to 1.17) 0.45 (0.37 to 0.54) 0.86 (0.72 to 1.03)
Co-amoxiclav 1.13 (0.82 to 1.57) 1.26 (1.06 to 1.50) 1.07 (0.79 to 1.44) 1.13 (0.89 to 1.44) 1.32 (1.16 to 1.49) 1.08 (0.90 to 1.29)
Cefalexin 1.41 (1.02 to 1.95) 1.18 (0.98 to 1.42) 1.06 (0.78 to 1.45) 1.25 (0.98 to 1.59) 1.17 (1.02 to 1.33) 0.87 (0.71 to 1.06)
Oxytetracycline 0.88 (0.55 to 1.40) 0.26 (0.17 to 0.42) 0.76 (0.48 to 1.21) 1.00 (0.72 to 1.38) 0.37 (0.28 to 0.50) 0.63 (0.47 to 0.84)
Other‡ 1.01 (0.75 to 1.38) 1.15 (0.97 to 1.35) 1.08 (0.82 to 0.42) 1.07 (0.86 to 1.34) 1.28 (1.14 to 1.44) 1.07 (0.90 to 1.26)
*Forty-six antibiotics (10 most frequently used: penicillin-V, flucloxacillin, cefradine, azithromycin, tetracycline, ampicillin, cefadroxil, ofloxacin, levofloxacin, nitrofurantoin).
†Thirty-one antibiotics (10 most frequently used: ciprofloxacin, flucloxacillin, tetracycline, cefradine, cefadroxil, azithromycin, metronidazole, nitrofurantoin, ampicillin, co-fluampicil).
‡Forty-nine antibiotics (10 most frequently used: trimethroprim, cefaclor, ciprofloxacin, flucloxacillin, cefradine, tetracycline, azithromycin, ampicillin, cefadroxil, nitrofurantoin, metronidazole).
CV, cardiovascular.
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1.29) and lowest in oxytetracycline therapies (0.68; 0.48
to 0.95) compared with clarithromycin therapies
(table 4; ﬁgure 2).
Within the URTI group, there were unadjusted rates
of 8.3 and 21.3 events per 10 000 therapies within 14
and 37 days of therapy initiation, respectively (table 3).
The adjusted 37-day risk of arrhythmia was lower in all
other antibiotics combined than in clarithromycin ther-
apies (0.94; 0.69 to 1.27). When analysing each of the
most frequently prescribed antibiotics for URTI separ-
ately, the adjusted 37-day risk of arrhythmia was highest
in co-amoxiclav therapies (1.22; 0.83 to 1.81) and lowest
in penicillin-V therapies (0.70; 0.50 to 0.99) compared
with clarithromycin.
Figure 2 Forest plot of the adjusted ORs (with 95% CIs) for 37-day all-cause mortality and CV and arrhythmia events, by
first-line antibiotic monotherapy and by indication. The reference category is treatment with clarithromycin. CV, cardiovascular.
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Within the LRTI and URTI combined group, there
were unadjusted rates of 14.0 and 34.4 arrhythmia
events per 10 000 therapies, within the 14 and 37 days
following therapy initiation (table 3). The adjusted
37-day risk of arrhythmia was lower in all other antibio-
tics combined than in clarithromycin therapies (0.86;
0.76 to 0.98). When analysing each of the most fre-
quently prescribed antibiotics for URTI separately, the
adjusted 37-day risk of arrhythmia was highest in
co-amoxiclav therapies (1.08; 0.90 to 1.29) and lowest in
penicillin-V therapies (0.57; 0.47 to 0.71) compared with
clarithromycin.
The 14-day risk of arrhythmia in LRTI showed no dif-
ference between other antibiotics combined and clari-
thromycin therapies (1.01; 0.80 to 1.27). However, in the
URTI group, the 14-day risk of arrhythmia was higher in
all other antibiotics combined than in clarithromycin
therapies (1.39; 0.80 to 2.41; table 4).
Interaction with statins not metabolised by cytochrome
CYP3A4
In total, 13 176 therapies for LRTI and 7613 therapies
for URTI were associated with prescriptions for statins
not metabolised by cytochrome CYP3A4: rosuvastatin,
pravastatin or ﬂuvastatin. Among these, there were 80
deaths in the LRTI group and 9 deaths in the URTI
group within 37 days of antibiotic initiation. In the
statin-associated therapies for LRTI, there were also 23
ﬁrst-ever CV events and 60 ﬁrst-ever arrhythmia events
within 37 days of antibiotic initiation; in those for URTI,
there were 9 ﬁrst-ever CV events and 24 ﬁrst-ever
arrhythmia events within 37 days of initiation.
Antibiotic therapies associated with rosuvastatin, pra-
vastatin or ﬂuvastatin included 801 clarithromycin ther-
apies for LRTI and 255 clarithromycin therapies for
URTI. Out of the 80 deaths in the statin-associated LRTI
therapies, 6 were in therapies for clarithromycin. None
of the nine deaths in the URTI therapies were in
patients receiving clarithromycin therapies.
There were four CV events and one arrhythmia event
in the statin-associated clarithromycin therapies for
LRTI. There were no CV events or arrhythmia events in
the statin-associated therapies for URTI.
A statistical model was not run due to the low number
of events.
DISCUSSION
This study was motivated by other studies concluding
that there was increased CV risk associated with macro-
lide antibiotics, including clarithromycin. Here, we
assessed the risk of a ﬁrst-ever CV event, as well as that of
all-cause mortality and ﬁrst-ever cardiac arrhythmia asso-
ciated with antibiotics prescribed for URTIs and LRTIs,
using clarithromycin as the referent.
Our ﬁndings do not support the hypothesis that treat-
ment of respiratory tract infections with clarithromycin
increased the risk of CV events, cardiac arrhythmias or
all-cause mortality. We found a large difference in anti-
biotic prescription patterns and event rates between
patients treated for upper and lower respiratory infec-
tions. The majority of penicillin-V and doxycycline pre-
scriptions were associated with URTI, whereas the
majority of clarithromycin prescriptions were associated
with LRTI, which dramatically increases CV event risks
due to differential age and comorbidity. However, when
the respiratory indication was not accounted for—as in
the study by Svanström et al6—our ﬁndings also showed
a signiﬁcant difference between penicillin-V and clari-
thromycin, with a 37-day OR of 0.29 (95% CI 0.21 to
0.39) for penicillin-V versus clarithromycin for all-cause
mortality. However, when upper and lower respiratory
indications for penicillin-V and clarithromycin were
investigated separately, a non-signiﬁcant reduction in
37-day all-cause mortality was found in penicillin-V for
URTI, with CIs spanning 1. Furthermore, pooled ﬁnd-
ings for doxycycline versus clarithromycin demonstrated
a lower 37-day OR of 0.45 (95% CI 0.37 to 0.54) for all-
cause mortality, but when split by indication the OR
became 0.58 (0.47 to 0.72) for LRTI and 0.84 (0.46 to
1.52) for URTI.
For all-cause mortality, there were differences in odds
in relation to the upper or lower location of the respira-
tory tract infection, but these patterns did not implicate
clarithromycin speciﬁcally: some antibiotics were asso-
ciated with a higher risk and others with a lower risk com-
pared with clarithromycin. The risks of a ﬁrst-ever CV
event and arrhythmia with clarithromycin treatment were
comparable with those observed with other antibiotics in
patients with upper or lower respiratory infections. This
was also the case where there was co-administration of
statins not metabolised by cytochrome CYP3A4.
This study differed from previous studies in that it was
more wide-ranging in the types of antibiotics evaluated.
Other studies targeted speciﬁc antibiotics.16
Three outcomes were analysed here: all-cause mortal-
ity, ﬁrst-ever CV event and ﬁrst-ever arrhythmia.
Macrolide antibiotics can inhibit the delayed potassium
rectiﬁer current in cardiac muscle cells and prolong the
repolarisation phase of the cardiac cycle, manifesting as
a lengthening of the QTc interval on an ECG17 18 and
increasing the risk of tachyarrhythmia such as torsades
des pointes.19 While extremely rare with oral administra-
tion of antibiotics at usual clinical doses and in people
with healthy hearts, the risks of cardiac arrhythmia are
potentially greater with administration of intravenous
doses, co-administration with other inhibitors of
CYP3A4, and in patients with heart disease, especially
those with left ventricular dysfunction or inherited
abnormalities of cardiac repolarisation (long QT syn-
drome). Despite this, our ﬁndings do not suggest an
excess risk associated with clarithromycin therapy com-
pared with other commonly prescribed antibiotics.
Following a recent publication evaluating various CV
end points in clarithromycin and amoxicillin in the ﬁrst
2 weeks of H. pylori eradication, we added the 14-day end
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point.13 Overall, we did not observe major differences
between our primary end points at 14 days compared
with 37 days.
Further, the relatively low risk of all-cause mortality
associated with commonly used antibiotics in primary
care suggests that any intrinsic risk of death and/or CV
event and/or arrhythmic event associated with clarithro-
mycin therapy is of minimal clinical importance at a
population level where there is no prior history of CVD
or arrhythmia. Any clinical impact from a possible proar-
rhythmic effect of clarithromycin appears to be offset by
the treatment of the underlying infection, reducing the
intensity and duration of inﬂammatory inﬂuences on
the vessel wall and myocardium. In our previous study of
antibiotic treatment failure in primary care, it was shown
that the antibiotic failure rates in LRTIs were lowest for
clarithromycin (19.2%) and amoxicillin (18.8%) in
2012. In order to prevent previous antibiotic interactions
impacting on outcomes, we applied a minimum period
of 90 days between antibiotic therapies. This meant that
the majority of therapies considered treatment failures
in the original study (switching to an alternative anti-
biotic within 30 days of treatment) were excluded from
this analysis; therefore, antibiotics with a higher treat-
ment failure rate were more likely to be excluded.
Since CPRD collates data from routine practice, there
will inevitably be missing and erroneous data, coding
imperfections and variation in medical practice. This is
mitigated to some extent by selecting only research
quality patient data from up-to-standard practices. A limi-
tation of this study was the inability to stratify our ana-
lyses by severity of infection. However, since we selected
only ﬁrst-line monotherapies for analysis, it may be
assumed that the associated infections were less severe
due to the single course of antibiotics required.
There was no conﬁrmation that the patients were com-
pliant with the antibiotic prescription’s dosage instruc-
tions and intended duration. Similarly, it is not known to
what extent prescribers advised patients to delay starting
the prescribed antibiotics.
We did not examine risk in patients ill enough to
require therapy with multiple antibiotics in combination;
nor did we examine patients whose antibiotic treatment
was initiated in hospital. Macrolides are often used for
indications other than respiratory tract infection, includ-
ing skin and soft tissue infections, but patients treated
for non-respiratory indications were not included in this
analysis. These ﬁndings therefore apply to patients aged
35 years and older managed for respiratory tract infec-
tions in primary care. It would be of value to investigate
patterns of antibiotic use and associated risk in people
with pre-existing CV disease.
CONCLUSION
CV events were much more likely to be associated with
LRTIs than with URTIs, irrespective of which antibiotic
was prescribed. There was no evidence of increased risk
of CV events in people without prior CV disease.
Prescribers should take the individual patient’s risk
proﬁle into consideration when prescribing an anti-
biotic; however, in this study of routine clinical data, no
evidence was found that clarithromycin caused more
cardiac events than other commonly used antibiotics.
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